TY - JOUR
T1 - Timing of Pediatric Drug Approval and Clinical Evidence Submitted to Regulatory Authorities
T2 - International Comparison Among Japan, the United States, and the European Union
AU - Hirota, Saeko
AU - Yamaguchi, Takuhiro
N1 - Funding Information:
No funding was received for this work. We thank Editage (www.editage.jp) for English-language editing. The partial cost of S.H.’s studying at the Tohoku University Graduate School of Medicine is paid by the EPS Corporation.
Publisher Copyright:
© 2019 The Authors Clinical Pharmacology & Therapeutics © 2019 American Society for Clinical Pharmacology and Therapeutics
PY - 2020/11/1
Y1 - 2020/11/1
N2 - Many prescription drugs approved for adult use lack pediatric labeling information, resulting in their off-label use in children. Drug regulatory authorities have developed legal and regulatory frameworks to promote pediatric drug development. However, the current state of pediatric indication approval and quality of efficacy evidence, which forms the basis of regulatory approvals, is unknown. Here, we analyzed novel therapeutics approved in Japan, the United States, and the European Union during 2005–2014 to investigate the timing and frequency of pediatric indication approval, and characterized the design of pediatric studies supporting regulatory approval. We found that the United States and European Union experienced a higher frequency of supplemental indication approval in pediatrics based on better-designed studies than Japan. The speed and efficiency of pediatric drug development will improve by coordinating pediatric studies on an international basis. The results also implied the necessity for a robust system of postmarketing monitoring of pediatric efficacy and safety.
AB - Many prescription drugs approved for adult use lack pediatric labeling information, resulting in their off-label use in children. Drug regulatory authorities have developed legal and regulatory frameworks to promote pediatric drug development. However, the current state of pediatric indication approval and quality of efficacy evidence, which forms the basis of regulatory approvals, is unknown. Here, we analyzed novel therapeutics approved in Japan, the United States, and the European Union during 2005–2014 to investigate the timing and frequency of pediatric indication approval, and characterized the design of pediatric studies supporting regulatory approval. We found that the United States and European Union experienced a higher frequency of supplemental indication approval in pediatrics based on better-designed studies than Japan. The speed and efficiency of pediatric drug development will improve by coordinating pediatric studies on an international basis. The results also implied the necessity for a robust system of postmarketing monitoring of pediatric efficacy and safety.
UR - http://www.scopus.com/inward/record.url?scp=85078667208&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078667208&partnerID=8YFLogxK
U2 - 10.1002/cpt.1757
DO - 10.1002/cpt.1757
M3 - Article
C2 - 31869436
AN - SCOPUS:85078667208
VL - 108
SP - 985
EP - 994
JO - Clinical Pharmacology and Therapeutics
JF - Clinical Pharmacology and Therapeutics
SN - 0009-9236
IS - 5
ER -